877134-79-7

Basic information

• Product Name: 1-(4-BroMo-2-fluorophenyl)urea
• Synonyms: 1-(4-BroMo-2-fluorophenyl)urea
• CAS NO: 877134-79-7
• Molecular Formula: C7H6BrFN2O
• Molecular Weight: 233.0377432
• Mol File: 877134-79-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-BroMo-2-fluorophenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BroMo-2-fluorophenyl)urea(877134-79-7)
• EPA Substance Registry System: 1-(4-BroMo-2-fluorophenyl)urea(877134-79-7)

Safety Data

• Hazardous Substances Data: 877134-79-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-(4-Bromo-2-fluorophenyl)urea is utilized as a key intermediate in the synthesis of various medicinal compounds, contributing to the development of new drugs. Its structural characteristics and reactivity enable the creation of a wide range of pharmaceutical agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(4-Bromo-2-fluorophenyl)urea serves as a building block for the assembly of other complex organic compounds. Its unique properties facilitate the formation of diverse chemical structures, expanding the scope of synthetic possibilities.
Used in Chemical Applications:
Due to its structural features, 1-(4-Bromo-2-fluorophenyl)urea holds potential as a valuable tool in various chemical applications, where its reactivity and properties can be harnessed to achieve specific objectives or outcomes.

Upstream product

• 1189-71-5 isocyanate de chlorosulfonyle 
• 367-24-8 4-bromo-2-fluoroaniline 

Relevant articles and documents

Novel ATP-competitive kinesin spindle protein inhibitors

Kinesin spindle protein (KSP), an ATPase responsible for spindle pole separation during mitosis that is present only in proliferating cells, has become a novel and attractive anticancer target with potential for reduced side effects compared to currently available therapies. We report herein the discovery of the first known ATP-competitive inhibitors of KSP, which display a unique activity profile as compared to the known loop 5 (L5) allosteric KSP inhibitors that are currently under clinical evaluation. Optimization of this series led to the identification of biphenyl sulfamide 20, a potent KSP inhibitor with in vitro antiproliferative activity against human cells with either wild-type KSP (HCT116) or mutant KSP (HCT116 D 130V). In a murine xenograft model with HCT116 D130V tumors, 20 showed significant antitumor activity following intraperitoneal dosing, providing in vivo proof-of-principle of the efficacy of an ATP-competitive KSP inhibitor versus tumors that are resistant to the other known KSP inhibitors.

NOVEL BIPHENYL COMPOUNDS AND THEIR USE

The invention is directed to certain biphenyl compounds. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Y are as defined below, and to pharmaceutically-acceptable salts thereo